M Reck
Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts
Putora P, Pöttgen C, Reck M, Blackhall F, Cappuzzo F, Besse B, Novello S, Garrido P, Felip E, O'Brien M, Paz Ares L, de Marinis F, Westeel V, Widder J, Peeters S, Troost E, Fischer G, Früh M, Califano R, Faivre-Finn C, Van Houtte P, McDonald F, Nestle U, Dziadziuszko R, Le Péchoux C, Ramella S, Belderbos J, Slotman B, De Ruysscher D. Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. Radiother Oncol 2020; 149:84-88.
Apr 20, 2020Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts
Apr 20, 2020Radiother Oncol 2020; 149:84-88
Putora Paul Martin, Pöttgen C, Reck M, Blackhall F, Cappuzzo F, Besse B, Novello S, Garrido P, Felip E, O'Brien M, Paz Ares L, de Marinis F, Westeel V, Widder J, Peeters S, Troost E G C, Fischer G F, Früh Martin, Califano R, Faivre-Finn C, Van Houtte P, McDonald F, Nestle U, Dziadziuszko R, Le Péchoux C, Ramella S, Belderbos J, Slotman B J, De Ruysscher D
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts
Früh M, De Ruysscher D, Westeel V, de Marinis F, Paz Ares L, O'Brien M, Felip E, Garrido P, Novello S, Besse B, Cappuzzo F, Califano R, Blackhall F, Reck M, Panje C, Putora P. Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. Lung Cancer 2020; 146:6-11.
Mar 30, 2020Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts
Mar 30, 2020Lung Cancer 2020; 146:6-11
Früh Martin, De Ruysscher D, Westeel V, de Marinis F, Paz Ares L, O'Brien M, Felip E, Garrido P, Novello S, Besse B, Cappuzzo F, Califano R, Blackhall F, Reck M, Panje C M, Putora Paul Martin
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
Jörger M, Behringer D, Ko Y, Hilger R, Roessler M, Kloft C, Henrich A, Moritz B, Miller M, Salamone S, Kopp H, Mayer F, von Pawel J, Kraff S, Fischer J, Eberhardt W, Gauler T, Mueller L, Reinmuth N, Reck M, Kimmich M, Jaehde U. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 2016; 27:1895-902.
Aug 8, 2016Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)
Aug 8, 2016Ann Oncol 2016; 27:1895-902
Jörger Markus, Behringer D M, Ko Y-D, Hilger R A, Roessler M, Kloft C, Henrich A, Moritz B, Miller M C, Salamone S J, Kopp H-G, Mayer F, von Pawel J, Kraff S, Fischer J R, Eberhardt W, Gauler T C, Mueller L, Reinmuth N, Reck M, Kimmich M, Jaehde U
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D'Addario G, Früh M, Reck M, Baumann P, Klepetko W, Felip E, ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5:v116-9.
May 1, 2010Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
May 1, 2010Ann Oncol 2010; 21 Suppl 5:v116-9
D'Addario G, Früh Martin, Reck M, Baumann P, Klepetko W, Felip E, ESMO Guidelines Working Group